Effect of Heat-Killed Lactobacillus casei DKGF7 on a Rat Model of Irritable Bowel Syndrome

Non-viable bacteria, referred to as “paraprobiotics,” have attracted attention as potentially safer alternatives to probiotics. The aim of this study was to investigate the efficacy of heat-killed Lactobacillus casei DKGF7 on the symptomatic improvement of irritable bowel syndrome (IBS) in a rat disease model and to elucidate the underlying mechanisms that contribute to the beneficial effects of heat-killed probiotics. Seven male Wistar rats were induced with IBS by restraint stress and administered heat-killed L. casei DKGF7 for four weeks and then compared with seven rats in the control group. Stool consistency measured four weeks after initial treatment was the primary outcome measure. To investigate the mechanism of action of the heat-killed bacteria on IBS, we measured serum corticosterone levels, inflammatory cytokines in colon tissue, and expression of tight junction proteins (TJPs) in the epithelium. The treatment group showed significantly better stool consistency scores than the control group at week 4, as well as at every measured time point (all p values < 0.05). The treatment group showed lower serum corticosterone levels, lower colonic inflammatory cytokine levels, and higher expression of TJPs compared with the control group. Paraprobiotics such as heat-killed L. casei DKGF7 can improve stool consistency in a rat IBS model, which may indicate a potential therapeutic strategy for IBS treatment.     

Matcha Green Tea Alleviates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice by Regulating Lipid Metabolism and Inflammatory Responses

Lately, matcha green tea has gained popularity as a beverage and food additive. It has proved to be effective in preventing obesity and related metabolic syndromes. However, the underlying mechanisms of its control effects against non-alcoholic fatty liver disease (NAFLD) are complicated and remain elusive. In the present study, we performed an in vivo experiment using male C57BL/6 mice fed with a high-fat diet and simultaneously treated with matcha for six weeks. Serum biochemical parameters, histological changes, lipid accumulation, inflammatory cytokines, and relevant indicators were examined. Dietary supplementation of matcha effectively prevented excessive accumulation of visceral and hepatic lipid, elevated blood glucose, dyslipidemia, abnormal liver function, and steatosis hepatitis. RNA sequencing analyses of differentially expressed genes in liver samples indicated that matcha treatment decreased the activity of lipid droplet-associated proteins and increased the activity of cytochrome P450 enzymes, suggesting improved metabolic capacity and liver function. The current study provided evidence for new dietary strategies based on matcha supplementation to ameliorate lipotoxicity-induced obesity and NALFD.     

强直性脊柱炎并发虹睫炎易感性与LMP2和LMP7基因多态性的探讨

目的　研究LMP基因多态性与强直性脊柱炎并发虹睫炎发病的关系.方法　应用PCR对正常人和病人进行HLA-B27检测以及LMP2和LMP7扩增.CfoI进行限制性酶切图谱分析.结果　强直性脊柱炎有虹睫炎(AS+AAU)病史以及单纯虹睫炎(AAU)患者LMP2基因BB纯合型较正常人以及强直性脊柱炎(AS)患者明显增高(P＜0.05).AS+AAU患者BB型OR＝3.6,AAU患者BB型OR＝5.83.LMP7基因多态性无明显差别.结论　在我国汉人中,LMP2基因多态性与AS+AAU以及AAU发病存在明显相关关系.     

Cag A Hp抗体测定与消化性溃疡和慢性胃炎的关系

目的 :探讨幽门螺杆菌细胞毒素相关基因蛋白 (CagA)抗体与消化性溃疡和慢性胃炎的关系。方法 :对132例消化性溃疡和慢性胃炎Hp幽门螺杆菌阳性的 118例病例 ,用ELISA方法进行CagA抗体检测。结果 :10 9例消化性溃疡中 ,CagA抗体阳性 90例 ,阳性率 82 .6 % ;9例慢性胃炎中 ,CagA抗体阳性 5例 ,阳性率 5 5 .6 %。消化性溃疡组CagA阳性率明显高于慢性胃炎组 (P <0 .0 1)。结论 :CagA抗体检测在消化性溃疡中有一定意义     

胃癌中P16与MDM2的免疫组化研究

目的 :检测胃肿瘤及正常胃组织中P16与MDM2的表达 ,探讨其在肿瘤凋亡中的相互关系。方法 :采用免疫组织化学方法 (SABC法 )。结果 :胃癌中P16阳性率为 69% ,MDM2阳性率为 75 % ,它们与正常胃组织及良性胃肿瘤相比差异均有显著性 (P <0 .0 5 )。结论 :在胃癌的细胞凋亡中 ,P16与MDM2均发挥了其各自对细胞凋亡的作用 ,为临床胃癌的组织学检测提供了理论依据 ,同时也支持胃癌的发生是多基因协同作用的过程     

细胞周期蛋白依赖性激酶抑制因子p27^kip1在骨肉瘤中表达的研究

目的：探讨细胞周期蛋白依赖性激酶抑制因子p27^kip1在骨肉瘤发生中的作用。方法：应用免疫组织化学方法（S－P法）检测27例传统骨肉瘤、4例皮质旁骨肉瘤和12例良性骨肉瘤中p27^kip1的表达,表达程度采用半定量方式判定。结果：骨肉瘤中p27^kip1表达的阳性率为100％,良性骨肿瘤中表达的阳性率为75％,两者间有非常显著性差异（P＜0．01）。骨肉瘤不同分化与阳性半定量间无相关性（P＞0．05）。结论：p27^kip1蛋白表达与骨肉瘤的发生有关,但与骨肉瘤的分化程度无关。     

Use of ivabradine for treatment of junctional ectopic tachycardia in post congenital heart surgery

Cardiac surgeries especially involving crux of the heart as performed in tetralogy of Fallot (TOF) and pulmonary stenosis are mainly responsible for junctional ectopic tachycardia (JET). Diversified antiarrhythmic agents have been used in an impressive way to treat JET but showed suboptimal efficacy and varied associated adverse effects. But, ivabradine has proved as final crusader for its treatment. We report our initial experience of 4 cases in last 6 months with ivabradine in the management of postoperative JET. Encouraged by various reports and our increasing experience with ivabradine in heart failure population, we have moved to ivabradine as the first drug of choice for postoperative JET. Bradycardia was the only significant adverse effect in our series. The availability of atrial and ventricular pacing wires or at least transvenous temporary pacing should be ensured before starting ivabradine.     

Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients

Allosensitization represents a major barrier to heart transplantation (HTx). We assessed the efficacy and safety of complement inhibition at transplant in highly sensitized heart transplant recipients. We performed a single-center, single-arm, open-label trial (NCT02013037). Patients with panel reactive antibodies (PRA) ≥70% and pre–formed donor-specific antibodies (DSA) were eligible. In addition to standard of care, patients received nine infusions of eculizumab during the first 2 months posttransplant. The primary composite endpoint was antibody-mediated rejection (AMR) ≥pAMR2 and/or left ventricular dysfunction during the first year. Secondary endpoints included hemodynamic compromise, allograft rejection, and patient survival. Twenty patients were included. Median cPRA and mean fluorescence intensity of immunodominant DSA were 95% (90%–97%) and 6250 (5000–10 000), respectively. Retrospective B cell and T cell flow crossmatches were positive in 14 and 11 patients, respectively. The primary endpoint occurred in four patients (20%). Survival at 1 year was 90% with no deaths resulting from AMR. In a prespecified analysis comparing treated patients to matched control patients, we observed a dramatic reduction in the risk of biopsy-proven AMR in patients treated with eculizumab (HR = 0.36, 95% CI = 0.14–0.95, p = .032). Our findings support the prophylactic use of complement inhibition for heart transplantation at high immunological risk. ClinincalTrials.gov, NCT02013037.     

Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation (SOT). Most PTLD cases are associated with Epstein–Barr virus (EBV) infection. The role of antiviral prophylaxis or rituximab therapy for prevention of PTLD in SOT recipients is controversial. In a nationwide cohort, we assessed the incidence, presentation, and outcome of histologically proven PTLD. We included 4765 patients with a follow-up duration of 23 807 person-years (py). Fifty-seven PTLD cases were identified; 39 (68%) were EBV positive (EBV+ PTLD). Incidence rates for EBV+ PTLD at 1, 2, and 3 years posttransplant were 3.51, 2.24, and 1.75/1000 py and 0.44, 0.25, and 0.29/1000 py for EBV− PTLD. We did not find an effect of antiviral prophylaxis on early and late EBV+ PTLD occurrence (early EBV+ PTLD: SHR 0.535 [95% CI 0.199–1.436], p = .264; late EBV+ PTLD: SHR 2.213, [95% CI 0.751–6.521], p = .150). However, none of the patients (0/191) who received a rituximab-containing induction treatment experienced PTLD, but 57 of 4574 patients without rituximab induction developed PTLD. In an adjusted restricted mean survival time model, PTLD-free survival was significantly longer (0.104 years [95% CI 0.077–0.131]) in patients receiving rituximab as induction treatment. This study provides novel data on the association of rituximab induction and reduced risk for PTLD.